Therapeutic siRNA for drug-resistant HER2-positive breast cancer

HER2 is overexpressed in about 20% of breast cancers and contributes to poor prognosis. Unfortunately, a large fraction of patients have primary or acquired resistance to the HER2-targeted therapy trastuzumab, thus a multi-drug combination is utilized in the clinic, putting significant burden on pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Shenda, Hu, Zhi, Ngamcherdtrakul, Worapol, Castro, David J., Morry, Jingga, Reda, Moataz M., Gray, Joe W., Yantasee, Wassana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924747/
https://www.ncbi.nlm.nih.gov/pubmed/26894975
http://dx.doi.org/10.18632/oncotarget.7409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924747/
https://www.ncbi.nlm.nih.gov/pubmed/26894975
http://dx.doi.org/10.18632/oncotarget.7409

Ejemplares similares